A bright future for protein kinase D1 as a drug target to prevent or treat pancreatic cancer.
A bright future for protein kinase D1 as a drug target to prevent or treat pancreatic cancer.
复制标题
蛋白激酶 D1 作为预防或治疗胰腺癌的药物靶点有着光明的前景。
DOI：
10.1080/23723556.2015.1035477
复制
发表时间：
2016
影响因子：
2.1
通讯作者：
Leitges,Michael
中科院分区：
文献类型：
--
作者：
Liou,Geou-Yarh;Storz,Peter;Leitges,Michael
Pancreatic ductal adenocarcinoma originates from acinar cells that undergo acinar-to-ductal metaplasia (ADM). ADM is initiated in response to growth factors, inflammation, and oncogene activation and leads to a de-differentiated, duct-like phenotype. Our recent publication demonstrated a transforming growth factor α-KrasG12D-protein kinase D1-Notch1 signaling axis driving the induction of ADM and further progression to pancreatic intraepithelial neoplasia. This suggests that protein kinase D1 might be an early marker for tumor development and a potential target for drug development.
